Entrada Therapeutics, Inc.

TRDA

Entrada Therapeutics, Inc.

TRDA

Insider Sentiment (TTM):

Last Purchase:2026-05-20Last Sale:2026-05-04Shares Purchased (TTM):134,603Shares Sold (TTM):483,587

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:24,589,292Shares Outstanding:41,836,275Institutional Ownership Pct.:58.78%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	99	76	90	93	72	68	101	78	185	68	68	52
Debt Securities Available For Sale Excluding Accru…	124	178	205	234	282	315	319	371	284	259	284	302
Restricted Cash Current	0	0	1	-	-	-	0	-	-	-	-	-
Contract With Customer Receivable After Allowance …	1	1	1	1	1	2	4	3	8	78	6	5
Prepaid Expense And Other Assets Current	9	11	9	10	14	19	16	13	12	9	12	24
Assets Current	233	267	306	338	369	403	440	465	490	414	370	383
Property Plant And Equipment Net	6	7	7	8	10	11	11	11	11	11	11	11
Restricted Cash Noncurrent	3	3	3	4	4	4	4	4	4	4	4	4
Operating Lease Right Of Use Asset	57	59	60	62	66	68	71	74	76	79	81	84
Other Assets Noncurrent	0	0	0	0	0	0	0	1	1	3	3	3
Assets	299	336	377	413	449	486	526	555	582	511	469	485
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	3	2	3	2	2	4	1	2	3	3	1
Accrued Liabilities Current	13	12	18	16	12	8	13	13	11	9	11	10
Taxes Payable Current	-	-	0	1	0	1	1	2	4	6	4	-
Operating Lease Liability Current	4	4	4	4	5	7	8	8	9	8	8	7
Deferred Revenue Current	0	0	0	0	1	1	14	46	60	148	132	148
Liabilities Current	21	19	24	24	20	18	39	71	86	174	159	165
Operating Lease Liability Noncurrent	44	45	47	48	49	50	52	54	56	58	60	62
Deferred Revenue	-	-	0	0	0	0	7	8	10	9	8	11
Liabilities	65	65	71	72	69	69	98	132	152	241	227	238
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	589	583	579	574	569	564	558	552	547	441	437	433
Accumulated Other Comprehensive Income Loss Net Of…	0	0	1	1	0	0	-0	1	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-356	-313	-273	-234	-190	-147	-129	-130	-116	-171	-195	-185
Stockholders Equity	233	271	306	341	380	417	429	422	430	269	242	247
Liabilities And Stockholders Equity	299	336	377	413	449	486	526	555	582	511	469	485
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	39	39	38	38	38	38	38	37	37	34	33	33
Shares Outstanding	39	39	38	38	38	38	38	37	37	34	33	33

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.21%	12.99%	-14.60%	-	-	-	-	-	-	-	-	-
2025	-11.83%	-19.84%	-24.13%	-8.07%	-2.52%	14.79%	47.77%	49.78%	64.46%	-11.57%	9.38%	-50.12%
2024	11.46%	2.67%	24.06%	-6.39%	7.97%	11.32%	6.82%	-6.50%	-31.04%	-12.44%	-32.14%	-32.47%
2023	-	-	-	0.06%	2.60%	-5.84%	-21.13%	-11.18%	-12.71%	8.65%	3.54%	21.72%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.89	13.90	12.53	14.08	18.64	21.88	11.15	6.59	5.70	2.38	2.33	2.32
Quick Ratio	10.47	13.32	12.17	13.66	17.94	20.86	10.73	6.40	5.56	2.33	2.25	2.17
Working Capital	211.33M	247.68M	281.80M	314.24M	349.34M	384.76M	400.56M	394.73M	403.73M	240.23M	210.98M	217.61M
Leverage & Debt
Debt to Equity	0.28	0.24	0.23	0.21	0.18	0.17	0.23	0.31	0.35	0.90	0.94	0.97
Debt Ratio	0.22	0.19	0.19	0.17	0.15	0.14	0.19	0.24	0.26	0.47	0.48	0.49
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.06	0.13	0.15	0.35	0.42	0.41	0.44	0.33	0.36	0.23
Per Share Metrics
Diluted EPS TTM	-3.93	-3.97	-3.47	-2.50	-1.77	0.60	1.68	1.35	2.94	0.68	-0.20	-0.63
Free Cash Flow Per Share TTM	-3.14	-3.20	-3.18	-2.22	-2.14	-1.41	-1.20	-0.43	-0.54	-2.80	4.06	3.34
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3,767.07%	-3,109.29%	-621.13%	-197.59%	-121.00%	2.39%	22.30%	26.85%	39.04%	14.57%	-2.45%	-38.60%
Net Profit Margin TTM	-3,537.73%	-2,895.05%	-565.48%	-168.16%	-92.30%	14.39%	31.13%	25.53%	43.63%	14.42%	-5.18%	-24.98%
Growth Metrics
Net Revenue Growth (1Y)	-94.10%	-96.67%	-87.94%	-71.42%	-66.80%	5.74%	63.38%	146.92%	451.22%	544.79%	-	-
Net Income Growth (1Y)	126.00%	-770.34%	-319.04%	-288.27%	-170.23%	5.52%	-1,081.69%	-352.42%	-226.80%	-129.50%	-92.93%	-79.60%
EPS Growth (1Y)	121.27%	-758.13%	-297.52%	-284.49%	-158.07%	-13.95%	-969.70%	-306.76%	-223.03%	-128.51%	-93.31%	-80.82%
Valuation Metrics
P/E TTM	-1.87	-3.18	-2.96	-2.32	-3.79	14.98	9.83	11.82	4.66	20.21	-74.60	-24.15
P/B TTM	1.33	1.95	1.39	0.71	0.73	0.89	1.50	1.54	1.13	1.76	2.06	2.13
P/S TTM	66.31	92.01	16.73	3.91	3.50	2.16	3.06	3.02	2.03	2.91	3.87	6.03
Market Cap	310.75M	527.97M	425.30M	240.48M	277.80M	371.31M	645.03M	649.26M	487.07M	474.65M	498.73M	525.84M
Enterprise Value	208.18M	448.24M	330.95M	143.25M	201.36M	299.52M	539.87M	567.26M	297.87M	402.27M	427.18M	470.01M
Calculated Values
Free Cash Flow TTM	-132.67M	-133.72M	-131.63M	-92.23M	-88.65M	-58.01M	-44.72M	-17.46M	-18.50M	-93.90M	134.19M	111.17M
Net Debt	-102.57M	-79.74M	-94.34M	-97.24M	-76.43M	-71.79M	-105.16M	-82.00M	-189.20M	-72.39M	-71.55M	-55.83M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-20Purchase

Owner: Zeiher, Bernhardt G

Title: -

Shares: 5,000

Price/Share: $5.86

Value: $29,300.00

Shares Owned: 5,000

Relationship: Director

Ownership: Indirect

2026-05-04Sale

Owner: Sethuraman, Natarajan

Title: President, Research & Develop.

Shares: 25,907

Price/Share: $15.39

Value: $398,708.73

Shares Owned: 216,317

Relationship: Officer

Ownership: Direct

2026-05-04Sale

Owner: Dowden, Nathan J

Title: President & COO

Shares: 15,000

Price/Share: $15.33

Value: $229,950.00

Shares Owned: 198,588

Relationship: Officer

Ownership: Direct

2026-04-01Sale

Owner: Wentworth, Kory James

Title: Chief Financial Officer

Shares: 2,500

Price/Share: $12.95

Value: $32,375.00

Shares Owned: 119,010

Relationship: Officer

Ownership: Direct

2026-03-10Sale

Owner: Wentworth, Kory James

Title: Chief Financial Officer

Shares: 11,388

Price/Share: $13.02

Value: $148,271.76

Shares Owned: 121,510

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-20	Zeiher, Bernhardt G	Director	-	Indirect	Purchase	5,000	5.86	$29,300.00	5,000	4
2026-05-04	Sethuraman, Natarajan	Officer	President, Research & Develop.	Direct	Sale	25,907	15.39	$398,708.73	216,317	4
2026-05-04	Dowden, Nathan J	Officer	President & COO	Direct	Sale	15,000	15.33	$229,950.00	198,588	4
2026-04-01	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	2,500	12.95	$32,375.00	119,010	4
2026-03-10	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	11,388	13.02	$148,271.76	121,510	4
2026-03-10	Dowden, Nathan J	Officer	President & COO	Direct	Sale	11,894	13.05	$155,216.70	198,588	4
2026-03-04	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	7,988	12.25	$97,853.00	137,987	4
2025-11-21	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	8,910	9.98	$88,921.80	110,026	4
2025-11-20	Baker, Felix, Baker Julia…	TenPercentOwner	-	Indirect	Purchase	28,867	9.07	$261,823.69	4,691,392	4
2025-11-14	Parmar, Kush	Director,TenPercentOwner	-	Indirect	Sale	200,000	8.80	$1,760,000.00	2,963,066	4
2025-11-14	5Am, Ventures V, L.P., Sc…	TenPercentOwner	-	Direct	Sale	200,000	8.80	$1,760,000.00	2,963,066	4
2025-11-12	Baker, Bros. Advisors (Gp…	TenPercentOwner	-	Indirect	Purchase	100,736	7.84	$789,770.24	4,664,924	4
2025-07-09	5Am, Opportunities I, L.P…	TenPercentOwner	-	Direct	Sale	20,065	7.50	$150,487.50	3,163,066	4
2025-07-09	Parmar, Kush	Director,TenPercentOwner	-	Indirect	Sale	27,000	7.50	$202,500.00	1,093,313	4
2025-07-01	Parmar, Kush	Director,TenPercentOwner	-	Indirect	Sale	25,000	7.12	$178,000.00	1,100,248	4
2025-07-01	Schwab, Andrew J., 5Am Op…	TenPercentOwner	-	Direct	Sale	18,578	7.12	$132,275.36	3,183,131	4
2025-03-17	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	1,784	10.67	$19,035.28	109,536	4
2024-12-11	Mpm, Bioventures 2018 Gp …	TenPercentOwner	-	Indirect	Sale	21,787	20.23	$440,751.01	4,381,062	4
2024-12-11	Mpm, Asset Management Inv…	TenPercentOwner	-	Indirect	Sale	21,787	20.23	$440,751.01	4,381,062	4
2024-12-03	Sethuraman, Natarajan	Officer	President, Research & Develop.	Direct	Sale	11,703	20.15	$235,815.45	144,997	4
2024-12-02	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	5,000	20.00	$100,000.00	73,849	4
2024-11-13	Sethuraman, Natarajan	Officer	President, Research & Develop.	Direct	Sale	2,700	20.04	$54,108.00	160,888	4
2024-11-11	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	8,637	19.98	$172,567.26	73,849	4
2024-11-06	Sethuraman, Natarajan	Officer	President, Research & Develop.	Direct	Sale	12,299	19.02	$233,926.98	164,997	4
2024-10-16	Sethuraman, Natarajan	Officer	President, Research & Develop.	Direct	Sale	600	18.00	$10,800.00	183,216	4
2024-09-26	Dowden, Nathan J	Officer	President & COO	Direct	Sale	847	16.00	$13,552.00	125,149	4
2024-09-09	Dowden, Nathan J	Officer	President & COO	Direct	Sale	1,904	15.07	$28,693.28	125,996	4
2024-09-09	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	3,195	14.97	$47,829.15	76,486	4
2024-09-09	Sethuraman, Natarajan	Officer	Chief Scientific Officer	Direct	Sale	2,642	15.09	$39,867.78	183,816	4
2024-08-16	Dowden, Nathan J	Officer	President & COO	Direct	Sale	27,097	16.48	$446,558.56	130,107	4
2024-07-15	Doshi, Dipal	Director,Officer	CEO	Direct	Sale	1,600	17.81	$28,496.00	334,475	4
2024-07-15	Sethuraman, Natarajan	Officer	Chief Scientific Officer	Direct	Sale	638	18.00	$11,484.00	188,814	4
2024-07-08	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	1,758	14.95	$26,282.10	81,412	4
2024-06-13	Doshi, Dipal	Director,Officer	CEO	Direct	Sale	1,000	16.17	$16,170.00	336,375	4
2024-05-20	Sethuraman, Natarajan	Officer	Chief Scientific Officer	Direct	Sale	9,675	15.19	$146,963.25	190,052	4
2024-05-17	Doshi, Dipal	Director,Officer	CEO	Direct	Sale	1,200	15.11	$18,132.00	337,375	4
2024-05-14	Kim, Peter S	Director	-	Direct	Purchase	25,000	14.59	$364,750.00	117,412	4/A
2024-05-14	Kim, Peter S	Director	-	Direct	Purchase	25,000	14.59	$364,750.00	92,412	4
2024-05-09	Kim, Peter S	Director	-	Direct	Purchase	2,200	14.25	$31,350.00	67,412	4
2024-04-08	Kim, Peter S	Director	-	Direct	Purchase	2,600	13.57	$35,282.00	62,936	4
2024-03-28	Kim, Peter S	Director	-	Direct	Purchase	1,512	13.75	$20,790.00	60,336	4
2024-03-26	Kim, Peter S	Director	-	Direct	Purchase	2,750	13.64	$37,510.00	58,824	4
2024-03-21	Kim, Peter S	Director	-	Direct	Purchase	704	13.24	$9,320.96	49,776	4
2024-03-06	Dowden, Nathan J	Officer	President & COO	Direct	Sale	1,826	12.32	$22,496.32	137,204	4
2024-03-06	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	4,086	12.31	$50,298.66	74,170	4
2024-02-15	Doshi, Dipal	Director,Officer	CEO	Direct	Sale	1,000	15.00	$15,000.00	243,279	4
2024-01-16	Doshi, Dipal	Director,Officer	CEO	Direct	Sale	1,000	15.99	$15,990.00	244,279	4
2023-12-26	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	94	16.67	$1,566.98	49,571	4
2023-12-20	Doshi, Dipal	Director,Officer	President and CEO	Direct	Sale	1,000	15.00	$15,000.00	245,279	4
2023-11-13	Doshi, Dipal	Director,Officer	President and CEO	Direct	Sale	1,000	16.23	$16,230.00	246,279	4
2023-10-17	Doshi, Dipal	Director,Officer	President and CEO	Direct	Sale	1,000	15.00	$15,000.00	247,279	4
2023-09-13	Doshi, Dipal	Director,Officer	President and CEO	Direct	Sale	1,000	15.00	$15,000.00	248,279	4
2023-09-06	Dowden, Nathan J	Officer	Chief Operating Officer	Direct	Sale	972	13.72	$13,335.84	48,168	4
2023-09-06	Kreher, Nerissa	Officer	Chief Medical Officer	Direct	Sale	892	13.73	$12,247.16	40,037	4
2023-09-06	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	950	13.74	$13,053.00	49,571	4
2023-08-14	Doshi, Dipal	Director,Officer	President and CEO	Direct	Sale	1,000	15.67	$15,670.00	201,069	4
2023-08-04	Kreher, Nerissa	Officer	Chief Medical Officer	Direct	Sale	6,898	14.14	$97,537.72	27,130	4
2023-07-11	Dowden, Nathan J	Officer	Chief Operating Officer	Direct	Sale	3,897	18.05	$70,340.85	35,376	4
2023-07-11	Sethuraman, Natarajan	Officer	Chief Scientific Officer	Direct	Sale	14,852	18.04	$267,930.08	153,447	4
2023-07-11	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	3,884	18.00	$69,912.00	36,747	4
2023-06-22	Dowden, Nathan J	Officer	Chief Operating Officer	Direct	Sale	7,097	16.02	$113,693.94	42,473	4
2023-06-21	Wentworth, Kory James	Officer	Chief Financial Officer	Direct	Sale	17,500	15.00	$262,500.00	27,957	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

58.78%

Inst. Shares: 24,589,292

Shares Outstanding: 41,836,275

2025-12-31

57.14%

Inst. Shares: 23,637,699

Shares Outstanding: 41,371,486

2025-09-30

66.64%

Inst. Shares: 27,629,992

Shares Outstanding: 41,462,567

2025-06-30

65.00%

Inst. Shares: 26,871,652

Shares Outstanding: 41,338,752

2025-03-31

66.54%

Inst. Shares: 27,330,053

Shares Outstanding: 41,073,732

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	24,589,292	41,836,275	58.78%
2025-12-31	23,637,699	41,371,486	57.14%
2025-09-30	27,629,992	41,462,567	66.64%
2025-06-30	26,871,652	41,338,752	65.00%
2025-03-31	27,330,053	41,073,732	66.54%
2024-12-31	27,505,353	37,306,363	73.73%
2024-09-30	26,809,168	40,629,602	65.98%
2024-06-30	26,445,832	34,180,549	77.37%
2024-03-31	23,174,816	33,497,072	69.18%
2023-12-31	23,194,414	33,050,319	70.18%
2023-09-30	23,009,789	33,281,287	69.14%
2023-06-30	22,794,124	33,163,320	68.73%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Entrada Therapeutics, Inc. (TRDA) — SEC Financial Statements & Analysis

Entrada Therapeutics, Inc. (TRDA) is a pharmaceutical preparations company, incorporated in DE. Entrada Therapeutics, Inc. trades on Nasdaq as: TRDA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Entrada Therapeutics, Inc. reported a -94.10% year-over-year revenue growth, a Debt-to-Equity ratio of 0.28x, a Price-to-Sales (P/S) ratio of 66.31x (TTM), a Price-to-Book (P/B) ratio of 1.33x (TTM), at a market cap of $310.75M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -94.10%
Debt To Equity: 0.28x
P/S TTM: 66.31x
P/B TTM: 1.33x
Market Cap: $310.75M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Entrada Therapeutics, Inc. in?

Entrada Therapeutics, Inc. (TRDA) operates in the Pharmaceutical Preparations industry.

What is TRDA's market cap?

Entrada Therapeutics, Inc. (TRDA) has a market capitalization of $310.75M as of 2026-06-30.

What exchange does TRDA trade on?

Entrada Therapeutics, Inc. (TRDA) trades on the Nasdaq.

Where is Entrada Therapeutics, Inc. incorporated?

Entrada Therapeutics, Inc. is incorporated in DE.